- Home
- BRLT vs OTLK Comparison
BRLT vs OTLK Comparison
Compare BRLT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | OTLK |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 42.3M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BRLT | OTLK |
|---|---|---|
| Price | $1.73 | $0.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.80 | ★ $3.83 |
| AVG Volume (30 Days) | 77.9K | ★ 13.1M |
| Earning Date | 11-05-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,597,000.00 | $1,413,535.00 |
| Revenue This Year | $5.92 | $2,048.59 |
| Revenue Next Year | $4.06 | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $1.25 | $0.50 |
| 52 Week High | $3.10 | $3.39 |
Technical Indicators
Market Signals| Indicator | BRLT | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 26.64 |
| Support Level | $1.61 | $0.50 |
| Resistance Level | $1.84 | $2.03 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 37.93 | 7.25 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.